Altimmune (ALT) Equity Average: 2011-2025
Historic Equity Average for Altimmune (ALT) over the last 13 years, with Sep 2025 value amounting to $173.5 million.
- Altimmune's Equity Average rose 21.36% to $173.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $173.5 million, marking a year-over-year increase of 21.36%. This contributed to the annual value of $158.8 million for FY2024, which is 16.29% down from last year.
- Per Altimmune's latest filing, its Equity Average stood at $173.5 million for Q3 2025, which was up 14.31% from $151.8 million recorded in Q2 2025.
- In the past 5 years, Altimmune's Equity Average registered a high of $243.9 million during Q2 2021, and its lowest value of $128.4 million during Q4 2024.
- Its 3-year average for Equity Average is $159.2 million, with a median of $162.7 million in 2024.
- Per our database at Business Quant, Altimmune's Equity Average soared by 440.30% in 2021 and then dropped by 27.62% in 2025.
- Altimmune's Equity Average (Quarterly) stood at $204.2 million in 2021, then declined by 4.43% to $195.2 million in 2022, then fell by 11.74% to $172.2 million in 2023, then declined by 25.43% to $128.4 million in 2024, then increased by 21.36% to $173.5 million in 2025.
- Its Equity Average stands at $173.5 million for Q3 2025, versus $151.8 million for Q2 2025 and $132.8 million for Q1 2025.